The Biograph Vision.X positron emission tomography/computed tomography (PET/CT) reportedly offers an industry-leading time of flight (TOF) and detector technology that facilitates the diagnosis of smaller lesions.
Offering an array of technological advantages with positron emission tomography/computed tomography (PET/CT), the Biograph Vision.X™ system has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The Biograph Vision.X features a time of flight (TOF) of 178 picoseconds and Optiso Ultra Dynamic Range (UDR) detector technology, according to Siemens Healthineers, the manufacturer of the device. Utilizing 3.2 x 3.2 mm lutetium oxyorthosilicate (LSO) crystal elements that provide enhanced spatial resolution in comparison to larger crystals, the company noted the UDR technology enables 48 mm3 volumetric resolution and temporal resolution of 178 ps.
“The Biograph Vision.X’s record-shattering, ultrafast time of flight delivers an image resolution that allows even the smallest lesions to rise above the noise,” said James Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “This extremely high level of resolution can help physicians detect small lesions and provide patients with a precise diagnosis.”
In order to optimize radiology workflow, Siemens Healthineers said the system’s built-in AIDAN intelligent imaging platform has a foundation of over 700 patents in machine learning and deep learning applications. The company added that the optional FlowMotion™ AI feature for the Biograph Vision.X device enables clinicians to personalize image acquisition with one click via a combination of anatomical AI and continuous bed motion.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.